The state of Nebraska currently has 7 active clinical trials seeking participants for Healthy research studies. These trials are conducted in various cities, including Omaha, Lincoln, Kearney and Grand Island.
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
Recruiting
The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.
Gender:
All
Ages:
Between 10 years and 25 years
Trial Updated:
02/20/2024
Locations: Be Well Clinical Studies Site Number : 8400077, Lincoln, Nebraska +3 locations
Conditions: Meningococcal Infection, Healthy Volunteers
BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects
Recruiting
This is a randomized, double-blind, placebo-controlled Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BT-600 when administered in single and multiple ascending doses to healthy participants. The study will enroll up to 48 participants, with participation lasting 2-3 weeks in addition to up to 28 days (about 4 weeks) for screening. The purposes of this study are to learn about the safety and tolerability of single and multiple rising oral... Read More
Gender:
All
Ages:
Between 19 years and 50 years
Trial Updated:
02/16/2024
Locations: Celerion, Lincoln, Nebraska
Conditions: Healthy
A Study of EDG-7500 in Healthy Adults
Recruiting
The purposes of this Phase 1 study of EDG-7500 are to: Learn about the safety of EDG-7500 after a single and multiple doses in healthy adults Learn about how EDG-7500 is tolerated after a single and multiples doses in healthy adults Evaluate the amount of EDG-7500 is in the blood and urine after single and multiple doses in healthy adults Evaluate the effect of a meal on the amount of EDG-7500 that is in the blood in healthy adults Evaluate whether the amount of EDG-7500 in the blood is similar... Read More
Gender:
All
Ages:
Between 18 years and 72 years
Trial Updated:
12/13/2023
Locations: Celerion, Lincoln, Nebraska
Conditions: Healthy Subjects
Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers
Recruiting
ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody designed to reduce the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Adults.
Gender:
All
Ages:
Between 19 years and 60 years
Trial Updated:
10/18/2023
Locations: Celerion, Lincoln, Nebraska
Conditions: Healthy Volunteers
A Study of DISC-3405 in Healthy Volunteers
Recruiting
This phase 1 study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of DISC-3405 in adult male and female healthy volunteers.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/06/2023
Locations: Celerion, Lincoln, Nebraska
Conditions: Healthy Volunteer
Integrated Cancer Repository for Cancer Research
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
Gender:
All
Ages:
Between 19 years and 110 years
Trial Updated:
09/29/2023
Locations: Mary Lanning Healthcare, Morrison Cancer Center, Hastings, Nebraska +7 locations
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, GIST, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, CNS Tumor, CNS Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
A Study of RBI-4000 in Healthy Participants
Recruiting
The primary purpose of the study is to evaluate the safety, reactogenicity, and immunogenicity of RBI-4000 administered at various dose levels via intramuscular injection and to determine the lowest dose of RBI-4000 necessary to elicit the rabies virus neutralizing antibody titer of equal or greater than (>=) 0.5 international unit per milliliter (IU/mL).
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
09/20/2023
Locations: Velocity Clinical Research, Omaha, Nebraska
Conditions: Healthy Volunteers